Anti-obesity drug use before professional treatment in Taiwan

Tsan Hon Liou, Chih Hsing Wu, Shu-Chen Chien, Wen Yuan Lin, Wei Jei Lee, Pesus Chou

研究成果: 雜誌貢獻文章

3 引文 (Scopus)

摘要

Between July 2004 and June 2005, a cross-sectional study was performed to determine the prevalence and patterns of anti-obesity medicine use among subjects seeking obesity treatment in Taiwan. Eighteen obesity outpatient clinics were selected via a random stratified sampling method and 1,060 first-visit clients (791 females and 269 males) aged above 18 years were enrolled and then completed a self-administered questionnaire. The prevalence of anti-obesity medicine use was 50.8%; more females than male used anti-obesity medicines (53.6% vs. 42.4%). Of the 1,060 subjects, 17.1% had used orlistat, 21.1% had taken sibutramine, and 18.3% had utilized unproven drugs such as cocktail therapy and other anti-obesity drugs. Furthermore, 23.6% and 22.4% of subjects indicated that they concurrently used Chinese herbal preparations and dietary supplements, respectively. Logistic regression analyses demonstrated that the odds ratio (OR) for anti-obesity medicine use was substantially higher in females (OR, 1.9; 95% CI, 1.3-2.6), those aged 18-24 years (OR, 1.6; 95% CI, 1.0-2.6), those with a body mass index (BMI) >35 kg/m2 (OR, 3.4; 95% CI, 2.1-5.7) and respondents concurrently using Chinese herbal preparations (OR, 1.7; 95% CI, 1.2-2.4) and dietary supplements (OR, 2.2; 95% CI, 1.6-3.1). In conclusion, the prevalence of anti-obesity drugs use is high among Taiwanese adults before they seek obesity treatment. Young, obese females, and those who had taken Chinese herbal preparations/dietary supplements had a high likelihood to report using anti-obesity medicines. Use of unproven weight-loss drugs is common and warrants further investigation.

原文英語
頁(從 - 到)580-586
頁數7
期刊Asia Pacific Journal of Clinical Nutrition
16
發行號3
出版狀態已發佈 - 九月 2007

指紋

Anti-Obesity Agents
Taiwan
Obesity
Odds Ratio
Plant Preparations
Dietary Supplements
sibutramine
Medicine
Ambulatory Care Facilities
Body Mass Index
Therapeutics
Cross-Sectional Studies
Logistic Models
Regression Analysis

ASJC Scopus subject areas

  • Medicine (miscellaneous)

引用此文

Anti-obesity drug use before professional treatment in Taiwan. / Liou, Tsan Hon; Wu, Chih Hsing; Chien, Shu-Chen; Lin, Wen Yuan; Lee, Wei Jei; Chou, Pesus.

於: Asia Pacific Journal of Clinical Nutrition, 卷 16, 編號 3, 09.2007, p. 580-586.

研究成果: 雜誌貢獻文章

Liou, Tsan Hon ; Wu, Chih Hsing ; Chien, Shu-Chen ; Lin, Wen Yuan ; Lee, Wei Jei ; Chou, Pesus. / Anti-obesity drug use before professional treatment in Taiwan. 於: Asia Pacific Journal of Clinical Nutrition. 2007 ; 卷 16, 編號 3. 頁 580-586.
@article{25e5d5bc08144851af54e1b107e75fd9,
title = "Anti-obesity drug use before professional treatment in Taiwan",
abstract = "Between July 2004 and June 2005, a cross-sectional study was performed to determine the prevalence and patterns of anti-obesity medicine use among subjects seeking obesity treatment in Taiwan. Eighteen obesity outpatient clinics were selected via a random stratified sampling method and 1,060 first-visit clients (791 females and 269 males) aged above 18 years were enrolled and then completed a self-administered questionnaire. The prevalence of anti-obesity medicine use was 50.8{\%}; more females than male used anti-obesity medicines (53.6{\%} vs. 42.4{\%}). Of the 1,060 subjects, 17.1{\%} had used orlistat, 21.1{\%} had taken sibutramine, and 18.3{\%} had utilized unproven drugs such as cocktail therapy and other anti-obesity drugs. Furthermore, 23.6{\%} and 22.4{\%} of subjects indicated that they concurrently used Chinese herbal preparations and dietary supplements, respectively. Logistic regression analyses demonstrated that the odds ratio (OR) for anti-obesity medicine use was substantially higher in females (OR, 1.9; 95{\%} CI, 1.3-2.6), those aged 18-24 years (OR, 1.6; 95{\%} CI, 1.0-2.6), those with a body mass index (BMI) >35 kg/m2 (OR, 3.4; 95{\%} CI, 2.1-5.7) and respondents concurrently using Chinese herbal preparations (OR, 1.7; 95{\%} CI, 1.2-2.4) and dietary supplements (OR, 2.2; 95{\%} CI, 1.6-3.1). In conclusion, the prevalence of anti-obesity drugs use is high among Taiwanese adults before they seek obesity treatment. Young, obese females, and those who had taken Chinese herbal preparations/dietary supplements had a high likelihood to report using anti-obesity medicines. Use of unproven weight-loss drugs is common and warrants further investigation.",
keywords = "Dietary supplement, Drug utilization, Off-label drugs, Orlistat, Sibutramine",
author = "Liou, {Tsan Hon} and Wu, {Chih Hsing} and Shu-Chen Chien and Lin, {Wen Yuan} and Lee, {Wei Jei} and Pesus Chou",
year = "2007",
month = "9",
language = "English",
volume = "16",
pages = "580--586",
journal = "Asia Pacific Journal of Clinical Nutrition",
issn = "0964-7058",
publisher = "HEC Press",
number = "3",

}

TY - JOUR

T1 - Anti-obesity drug use before professional treatment in Taiwan

AU - Liou, Tsan Hon

AU - Wu, Chih Hsing

AU - Chien, Shu-Chen

AU - Lin, Wen Yuan

AU - Lee, Wei Jei

AU - Chou, Pesus

PY - 2007/9

Y1 - 2007/9

N2 - Between July 2004 and June 2005, a cross-sectional study was performed to determine the prevalence and patterns of anti-obesity medicine use among subjects seeking obesity treatment in Taiwan. Eighteen obesity outpatient clinics were selected via a random stratified sampling method and 1,060 first-visit clients (791 females and 269 males) aged above 18 years were enrolled and then completed a self-administered questionnaire. The prevalence of anti-obesity medicine use was 50.8%; more females than male used anti-obesity medicines (53.6% vs. 42.4%). Of the 1,060 subjects, 17.1% had used orlistat, 21.1% had taken sibutramine, and 18.3% had utilized unproven drugs such as cocktail therapy and other anti-obesity drugs. Furthermore, 23.6% and 22.4% of subjects indicated that they concurrently used Chinese herbal preparations and dietary supplements, respectively. Logistic regression analyses demonstrated that the odds ratio (OR) for anti-obesity medicine use was substantially higher in females (OR, 1.9; 95% CI, 1.3-2.6), those aged 18-24 years (OR, 1.6; 95% CI, 1.0-2.6), those with a body mass index (BMI) >35 kg/m2 (OR, 3.4; 95% CI, 2.1-5.7) and respondents concurrently using Chinese herbal preparations (OR, 1.7; 95% CI, 1.2-2.4) and dietary supplements (OR, 2.2; 95% CI, 1.6-3.1). In conclusion, the prevalence of anti-obesity drugs use is high among Taiwanese adults before they seek obesity treatment. Young, obese females, and those who had taken Chinese herbal preparations/dietary supplements had a high likelihood to report using anti-obesity medicines. Use of unproven weight-loss drugs is common and warrants further investigation.

AB - Between July 2004 and June 2005, a cross-sectional study was performed to determine the prevalence and patterns of anti-obesity medicine use among subjects seeking obesity treatment in Taiwan. Eighteen obesity outpatient clinics were selected via a random stratified sampling method and 1,060 first-visit clients (791 females and 269 males) aged above 18 years were enrolled and then completed a self-administered questionnaire. The prevalence of anti-obesity medicine use was 50.8%; more females than male used anti-obesity medicines (53.6% vs. 42.4%). Of the 1,060 subjects, 17.1% had used orlistat, 21.1% had taken sibutramine, and 18.3% had utilized unproven drugs such as cocktail therapy and other anti-obesity drugs. Furthermore, 23.6% and 22.4% of subjects indicated that they concurrently used Chinese herbal preparations and dietary supplements, respectively. Logistic regression analyses demonstrated that the odds ratio (OR) for anti-obesity medicine use was substantially higher in females (OR, 1.9; 95% CI, 1.3-2.6), those aged 18-24 years (OR, 1.6; 95% CI, 1.0-2.6), those with a body mass index (BMI) >35 kg/m2 (OR, 3.4; 95% CI, 2.1-5.7) and respondents concurrently using Chinese herbal preparations (OR, 1.7; 95% CI, 1.2-2.4) and dietary supplements (OR, 2.2; 95% CI, 1.6-3.1). In conclusion, the prevalence of anti-obesity drugs use is high among Taiwanese adults before they seek obesity treatment. Young, obese females, and those who had taken Chinese herbal preparations/dietary supplements had a high likelihood to report using anti-obesity medicines. Use of unproven weight-loss drugs is common and warrants further investigation.

KW - Dietary supplement

KW - Drug utilization

KW - Off-label drugs

KW - Orlistat

KW - Sibutramine

UR - http://www.scopus.com/inward/record.url?scp=34648818932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34648818932&partnerID=8YFLogxK

M3 - Article

C2 - 17704041

AN - SCOPUS:34648818932

VL - 16

SP - 580

EP - 586

JO - Asia Pacific Journal of Clinical Nutrition

JF - Asia Pacific Journal of Clinical Nutrition

SN - 0964-7058

IS - 3

ER -